Dr. Elizabeta Nemeth is interested in regulation of iron metabolism and the pathogenesis of iron disorders. There are multiple interactions between iron metabolism and cancer. On one hand, iron overload promotes carcinogenesis. At the other end of the spectrum, cancer-related inflammation leads to iron-restriction, hypoferremia and anemia of cancer. Her goal is to understand the interactions between cancer and iron metabolism and use the knowledge to develop appropriate therapeutic interventions.
Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, Callander N, Katodritou E, Tussing-Humphreys L, Rivera S, Vanderkerken K, Lichtenstein A, Ganz T. In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood. 2010 Nov 4;116(18):3635-44. Epub 2010 Aug 2.
Nemeth E. Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol. 2010;2010:750643. Epub 2009 Dec 24.
Fernandes A, Preza GC, Phung Y, De Domenico I, Kaplan J, Ganz T, Nemeth E. The molecular basis of hepcidin-resistant hereditary hemochromatosis. Blood. 2009 Jul 9;114(2):437-43. Epub 2009 Apr 21.
Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, Ganz T, Lichtenstein A. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008 Jun 1;14(11):3262-7.
Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007 May;92(5):583-8.